🎉 Share Your 2025 Year-End Summary & Win $10,000 Sharing Rewards!
Reflect on your year with Gate and share your report on Square for a chance to win $10,000!
👇 How to Join:
1️⃣ Click to check your Year-End Summary: https://www.gate.com/competition/your-year-in-review-2025
2️⃣ After viewing, share it on social media or Gate Square using the "Share" button
3️⃣ Invite friends to like, comment, and share. More interactions, higher chances of winning!
🎁 Generous Prizes:
1️⃣ Daily Lucky Winner: 1 winner per day gets $30 GT, a branded hoodie, and a Gate × Red Bull tumbler
2️⃣ Lucky Share Draw: 10
I have a friend who is in the rebate business, and some time ago, he was liquidated on $PIPPIN. Since then, I've been debating whether the small K-line manipulators are all in cahoots. Various conspiracy theories keep popping up, but then I think—what if they’re not?
Is it possible that large funds accidentally stumbled into a scam coin? Since they’re here, might as well test it out. This time’s needle insertion, I tend to interpret it as a probing of the small K-line’s margin capacity.
Looking back at the previous performance of the manipulators, honestly, their strength is average. They don’t dare to hard push the needle; instead, they deliberately lower the price to near the small K-line’s cost line, which is a typical tactic of showing weakness. Everyone thus relaxed their vigilance. This time, all their methods have been exposed.
From a different perspective, if the next needle is coming, the intensity will definitely need to double. At least aiming for 1.2 there. If they still dare to go lower, the current price level can be considered for bold needle insertion. Of course, this is under the condition of a good take-profit plan. Doubling the gains isn’t easy, but the key is to hold on.
I want to emphasize risk management—such operations must set proper take-profit points, don’t be greedy.